Cellergy Therapeutics

Company Overview

Snapshot

Founded in May 2021, Cellergy Therapeutics operates with 1–10 employees. The company has secured funding across one round from XT Group and Fresh Fund. In May 2025, the company was featured in a Haaretz article highlighting mitochondria as a new frontier in healing and a medical breakthrough.

Business overview

Cellergy Therapeutics is a Health Tech & Life Sciences company focused on revolutionizing the treatment of degenerative and metabolic diseases. The company's core technology involves producing large quantities of mitochondrial product from human primary sources for systemic, repeated administration. Cellergy delivers fully matched allogeneic purified mitochondria via IV to restore cellular energy production and enhance cell function, targeting major systemic indications such as CNS disorders, muscle degeneration, and aging. It operates within the Pharma & Medical Biotechnology sector, specifically in the areas of Biologicals and Cells, serving the Healthcare & Life Sciences market, including Pharmaceuticals and Biotechnology.

Strategic signal

In May 2025, Cellergy Therapeutics was highlighted in a Haaretz article, positioning mitochondria as a new frontier in healing and a medical breakthrough. This signals growing recognition and validation of the company's innovative mitochondrial transplantation therapy, which aims to restore cellular energy and combat degenerative diseases, potentially attracting further investor interest and strategic partnerships in the biotechnology and regenerative medicine fields.

Company Intelligence Q&A

What is Cellergy Therapeutics' primary focus?

Cellergy Therapeutics is focused on revolutionizing the treatment of degenerative and metabolic diseases by restoring cellular energy through innovative mitochondrial transplantation therapy.

When was Cellergy Therapeutics founded?

Cellergy Therapeutics was founded in May 2021.

Which investors participated in Cellergy Therapeutics' funding round?

In September 2025, Cellergy Therapeutics received funding from XT Group and Fresh Fund.

What is the core technology behind Cellergy Therapeutics' approach?

Cellergy Therapeutics' core technology involves producing large quantities of mitochondrial product from human primary sources for systemic, repeated administration, delivering fully matched allogeneic purified mitochondria via IV.

What recent media attention has Cellergy Therapeutics received?

In May 2025, Cellergy Therapeutics was featured in a Haaretz article titled 'MITOCHONDRIA: THE NEW FRONTIER IN HEALING A MEDICAL BREAKTHROUGH', highlighting its innovative approach.